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ABSTRACT: Reports on chemical immobilization of proteins and enzymes first appeared
in the 1960s. Since then, immobilized proteins and enzymes have been widely used in
the processing of variety of products and increasingly used in the field of medicine.
Here, we present a review of recent developments in immobilized enzyme use in medi-
cine. Generally speaking, the use of immobilized enzyme in medicine can be divided into
two major categories: biosensors and bioreactors. A brief overview of the evolution of the
biosensor and bioreactor technology, of currently existing applications of immobilized
enzymes, of problems that researchers encountered, and of possible future develop-
ments will be presented. © 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association
J Pharm Sci 89: 979–990, 2000
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INTRODUCTION
Reports on chemical immobilization of proteins
and enzymes first appeared ∼30 years ago. Since
then, immobilized proteins have been widely used
for the processing of a variety of products span-
ning industries from food to environmental con-
trol. In addition to their use in processing, immo-
bilized proteins and enzymes have also been
found useful in many bioanalytical and biomedi-
cal applications. These applications include the
use of immobilized antibodies or antigens in bio-
affinity chromatography, of immobilized recep-
tors or ligands in the study of their interactions,
and of immobilized cells in biosensors. Although
there have been a large number of articles dis-
cussing immobilization techniques of proteins
and enzymes as well as their applications in cer-
tain fields,1–3 a review on the applications of im-
mobilized proteins and enzymes in medicine and
particularly during the past decade (i.e., 1990s) is
still lacking.
Presently, immobilized proteins/enzymes are
used routinely in the medical field, such as in the
diagnosis and treatment of various diseases. For
example, immobilized antibodies, receptors, or
enzymes are used in biosensors and ELISA for the
detection of various bioactive substances in the
diagnosis of disease states; encapsulated enzymes
are also used in bioreactors for the removal of
waste metabolites and correction of inborn meta-
bolic deficiency. Moreover, the use of artificial
cells as well as the development of controlled-
release drug delivery systems to release encapsu-
lated enzymes or proteins may also be considered
a form of immobilized enzyme use. However, this
article will concentrate only on the review of cur-
rent applications of traditionally defined immobi-
lized enzymes in medicine; specifically in the ar-
eas of biosensors and bioreactors.
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IMMOBILIZED ENZYME USED
IN BIOSENSORS
Enzyme-based electrodes represent a major appli-
cation of immobilized enzymes in medicine. The
high specificity and reactivity of an enzyme to-
wards its substrate are properties being exploited
in biosensor technology. Biosensors possess ad-
vantages such as reliability, sensitivity, accuracy,
ease of handling, and low-cost compared with con-
ventional detection methods. These characteris-
tics, in combination with the unique properties of
an enzyme already mentioned, render an enzyme-
based biosensor ideal for biomedical applications.
A summary of some recent applications of en-
zyme-based sensors in clinical diagnosis is pre-
sented in Table 1. Our discussion on this subject
will be classified into four different categories: en-
zyme immobilization, sensitivity and selectivity,
optical biosensor, and implantable biosensor.
Enzyme Immobilization
An enzyme-based electrochemical sensor is for-
mulated by immobilizing a thin layer of en-
zyme(s) on the surface of the membrane of an
electrode. The analyte to be monitored diffuses
into the enzyme layer where the catalytic reaction
occurs, either consuming a substrate or generat-
ing a product that can be detected electrochemi-
cally. The electroactive species produced are
monitored either potentiometrically or ampero-
metrically, and the electrochemical signal can be
correlated to the concentration of the analyte to
be measured. The immobilization method may af-
fect the activity of the immobilized enzyme, and
thus it can contribute significantly to the sensi-
tivity of the biosensor.
Immobilization methods that are currently be-
ing used include absorption, cross-linking, and
self-assembly, whereas materials into which en-
zymes are incorporated include carbon paste, con-
ducting or nonconducting polymers, and different
types of gels. The ultimate aim of these efforts is
to develop an inexpensive and easy-to-prepare
method that can yield a stable matrix possessing
the maximum retention of the biological activity
of the immobilized enzyme. Generally speaking,
physical entrapment of enzymes in polymeric
membranes is one of the most advantageous
methods because it is rapid and simple, the re-
tained enzyme activity is usually quite high, plus
no chemical reaction that may lead to the inacti-
vation of the enzyme is required. The major limi-
tation of physical entrapment is, however, that
unlike chemical immobilization where all types of
substrates, whether they are large or small, can
all reach the immobilized enzyme for interaction,
the physically entrapped enzyme is prohibited
from interaction with large substrates that are
unable to diffuse into the matrix. Therefore, for
Table 1. Application of Biosensor in Medicine





Glucose Glucose oxidase/glucose dehydrogenase ∼50 mM ∼5 ∼6 4–8
Lactate Lactate oxidase ∼27 mM ∼1 ∼9 9, 10
Oxalate Oxalate oxidase ∼1 mM 2∼40 ∼24 11, 12
Urea Urease ∼100 mM ∼5 ∼6 13, 14
Glutamate Glutamate oxidase ∼200 mM ∼1 15, 16
Carnitine Carnitine dehydrogenase and diaphorase ∼1 nM ∼3 ∼3 17
Theophylline Theophylline oxidase ∼30 mM ∼1 18
Creatine and
creatinine
Creatininase, creatinase and sarcosine
oxidase
∼30 mM ∼4 19, 20
Cholesterol Cholesterol oxidase ∼3 mM 21, 22
Amino acid Amino acid oxidase ∼10 mM ∼3 ∼2 23
Acetylcholine
and choline
Acetylcholine esterase and choline
oxidase
∼100 mM ∼2 ∼6 24–26
Bilirubin Hemoglobin and glucose oxidase 27, 28
g-Aminobutyric
acid
Catalase and G-glutamate oxidase ∼10 nM 29
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assaying a large substrate, chemically immobi-
lized enzyme should be used.
In search of suitable matrices for enzyme im-
mobilization, there has been a growing interest in
attaching the enzymes to the solid electrolyte Na-
fion. The Nafion membrane possesses a high sur-
face adhesion property and a low swelling capa-
bility in aqueous media. Being a negatively
charged polyelectrolyte matrix, Nafion exhibits a
reduced permeability to negatively charged sub-
stances, therefore improving the sensor selectiv-
ity and virtually eliminating the interference of
reductants such as ascorbate and acetaminophen.
On the other hand, a Nafion film possesses a high
ability to entrap positively charged redox-active
compounds that can be used as mediators in bio-
electrocatalytic reactions. In addition, the poly-
electrolyte nature of the Nafion film can stabilize
the ionic strength at the electrode surface,
thereby preventing electrode fouling and increas-
ing the dynamic range for analyte detection.




and poly(o-phenylenediamine)35 have also been
used recently in preparing biosensors because of
their advantageous properties of high oxygen
solubility, decent hydrophilicity, good biocompat-
ibility, reasonable mechanical strength, and anti-
fouling.36 In addition, immobilization of heparin
on artificial surfaces has also been extensively ex-
plored in an attempt to create a thromboresistant
surface for the use of the biosensors in vivo.37,38
The low-temperature sol–gel process is another
current attractive avenue for the immobilization
of enzymes. Numerous sol–gel-based biosensors
have been reported, and enzymes have been
trapped in either inorganic or organic-modified
inorganic materials such as silica,39,40 alumina,41
silane,42 and silver43 matrixes. Compared with
membranes made of other inorganic materials,
such as clays43 and zeolites44 that limit enzyme
immobilization because of their molecular dimen-
sions, the porous organic or inorganic sol–gel ma-
trix possesses physical rigidity, chemical inert-
ness, high biodegradable property, and thermal
stability. In addition, the sol–gel matrix yields in-
significant swelling in both aqueous and organic
solutions.
Sensitivity and Selectivity
Amperometric biosensors based on oxidase en-
zymes that generate hydrogen peroxide are the
most widely used biosensors. Glucose determina-
tion utilizing the enzyme glucose oxidase (GOD)
is an example of such an amperometric biosensor,
and the principle of such glucose electrodes is
based on the following reactions:
Immobilized layer: glucose + O2 →
gluconic acid + H2O2
Electrode: H2O2 → O2 + 2H
+ + 2e−
Obviously, this type of sensor is based on either
oxygen depletion (cathodic) or the electrochemical
oxidation of H2O2 (anodic). However, direct oxi-
dation of H2O2 requires a highly positive over-
potential, and hence this type of sensor suffers
from interferences due to the presence of easily
oxidizable species in the biological fluids. Al-
though the cathodic measurement of molecular
oxygen concentration is perfectly suitable for glu-
cose monitoring in solution, these devices also
suffer potential difficulties when operating in vivo
or in undiluted biological samples where the re-
sponse is limited by physiological amounts of oxy-
gen available. To solve the oxygen deficit problem,
attempts have been made in glucose detection to
use an additional catalase in recycling O2 from
H2O2,
45 or to develop approaches that allow O2 to
be delivered externally to the electrode surface,
thereby producing an excess level of O2 (compared
with that of glucose) at the electrode surface.46
This excess amount of O2 will allow for better
regulation of the reaction environment and,
hence, oxygen (instead of glucose) does not be-
come the limiting reagent in the reaction. How-
ever, incorporation of catalase is undesirable for
in vivo use of microelectrodes because a variation
in the O2 level in the surrounding medium may
cause fluctuation in electrode response and thus a
second electrode would be needed to measure the
actual O2 level so that the accurate concentration
of the substrate can be determined. The main con-
cern associated with the use of an external O2
delivery system, on the other hand, is the diffi-
culty in regulating the oxygen generation or sup-
ply, leading to possible introduction of an inad-
equate amount of oxygen to the electrode mem-
brane.46
Another approach to solve this oxygen defi-
ciency problem is to place a diffusion-restriction
membrane on top of the enzyme membrane. Such
a diffusion-limiting membrane will yield high
oxygen permeability but low glucose permeabil-
ity, thereby providing a minimal concentration of
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glucose within the enzyme layer and a relatively
constant amount of oxygen.30–35 Alternatively,
some artificial electron acceptors or mediators,
such as ferrocenes,47 quinones,48 diaminoben-
zenes,49 and TTF,50 have also been used to mini-
mize the sensitivity to oxygen of the enzyme-
based electrodes. These electron-transfer media-
tors, which are retained at the electrode surface
using a membrane or entrapped in an electron-
generated film at the surface, facilitate electron
transfer between an electrode and a redox-active
biological molecule, ensuring the attainment of a
high signal-to-noise ratio. In addition to minimiz-
ing oxygen sensitivity, coupled mediated sensing
systems, in which the mediator is attached to ei-
ther the electrode or to the enzyme, could also
provide a faster electron transfer, improved bio-
sensor lifetime,51 and reducing susceptibility to
interferences from other electrochemically active
species because of the low potential generally
needed for oxidation of the mediators.52
In addition, increased sensitivity and selectiv-
ity of a enzyme-based electrode can also be ob-
tained by modifying the electrode surface with
semiconducting films using electropolymerization
of a redox monomer, such as phenazine,53
phenoxazine and phenothiazine derivatives,54
viologens,55 and thionine.56 Polymer-modified
electrodes with a three-dimensional distribution
of mediators are preferred over a monolayer dis-
tribution of mediators for the design of biosensors
because a much larger catalytic response of the
polymer coating will be obtained because of the
volume effect. In general, the major obstacles that
prevented rapid progress in the practical applica-
tion of the semiconducting electrode in glucose
sensing in the early of 1990s were: (1) physical
instability and light sensitivity of the semicon-
ductor structures; (2) dramatic decrease in the
biosensor response to the change of buffer condi-
tions and the ionic strength of the solution; and
(3) limitation in the dynamic range of the biosen-
sor response due to an insufficient concentration
of dissolved oxygen in the measured samples.57
However, with the advent of application of an ad-
ditional semipermeable membrane on top of the
enzyme layer and of enzyme field effect transis-
tors,58,59 the stability, sensitivity, and dynamic
range of semiconducting sensors have recently
been greatly improved.60
Because not all enzyme-catalyzed reactions are
involved with transducer-active compounds (e.g.,
H+, O2, OH
−), only a limited number of substances
can be determined by using a sensor consisting of
a single enzyme. In this regard, the use of coupled
enzyme reactions for analyte conversion provides
a more favorable alternative. In such cases, the
primary products produced by the reaction of the
analyte with the first enzyme is further converted
by a second enzyme to produce products detect-
able by a transducer.61 Coupled enzyme reactions
are also employed to filter out chemical signals by
eliminating the interference on the enzyme and/
or tranducer reaction caused by other constitu-
ents in the sample.62,63 Alternatively, for certain
measurements, an enzyme-based sensor can also
be constructed by using the inhibition of the en-
zyme activity. In this case, the analyte is not a
substrate but an inhibitor to the specific reaction
of the enzyme. A reduction in the electrical signal
can then be inversely correlated to the analyte
concentration in the solution.64,65
Glucose dehydrogenase-based electrodes have
also been developed to potentiometrically or am-
perometrically monitor glucose concentration. In
most instances, glucose dehydrogenase systems
require the presence of NAD or NADP. Require-
ments also depend on oxygen saturation of the
sample and whether or not a redox mediator has-
been incorporated7,8 to enhance glucose detection.
Optical Biosensor
In addition to the electrochemical transduction
systems, interest in optical biosensors based on
immobilized enzymes has also been gradually
growing. Immobilization techniques used in opti-
cal sensors include adsorption,66 physical entrap-
ment,67 and photocontrolled polymerization.68
The sol–gel method of entrapping enzymes in
transparent silicate matrices is especially suit-
able in optical biosensors because it allows for the
monitoring of chemical reactions of immobilized
proteins by changes in the visible absorption spec-
tra.67 Fiberoptic biosensors for monitoring glu-
cose,69 cholesterol,70 phospholipid,71 and biliru-
bin72 have been reported. Recently, the determi-
nation of analyte concentration is based on the
measurement of the oxygen partial pressure in
the analyte sample. In these devices, changes in
the oxygen level were measured via quenching of
the fluorescence of an oxygen-sensitive dye. In the
case of the glucose sensor, the enzymatic deple-
tion of oxygen, which is the result of transforma-
tion of the glucose by the immobilized enzyme
glucose oxidase, leads to a decrease in the fluo-
rescence quenching efficiency of the oxygen-
sensitive dye element by O2; as a result, the in-
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crease in the fluorescence intensity of the sensor
during the enzymatic reaction corresponds to the
glucose concentration.69 Alternatively, H2O2 pro-
duced in the oxidation of glucose by glucose oxi-
dase can also be used for glucose detection
through its further reaction with a dye precursor
to produce a colored dye by the enzyme peroxi-
dase. The rate of the colored dye formation is in-
dicative of the glucose concentration.73 The main
drawback of this technology, however, lies in the
rather slow response time for such fiberoptic bio-
sensors, primarily because of the indirect nature
for the analyte measurements. However, enzymes
containing a flavin adeninedinucleotide (FAD) re-
action site, such as glucose oxidase, cholesterol
oxidase, and lactate monooxygenase, exhibit
characteristic absorption spectrum with bands at
377 and 455 nm. On the addition of the analyte,
the enzyme is almost completely decolorized;
thus, the development of reagent-free sensor is
also being explored.67,74 These sensors offer the
advantage of more rapid communication with the
optrode for response. Recently, FAD- or ferrocene-
reconstituted enzymes have been used in the en-
zymatic sensor and should offer some benefits in
future development of the fiberoptic biosensing
devices.75,76
Implantable Biosensor
Biosensors, in addition to the benefits of simpli-
fying existing biochemical measurements, offer
the advantage of allowing continuous and real-
time monitoring. In addition to their main func-
tion in monitoring the rapid changes in blood ana-
lyte concentrations, biosensors provide an essen-
tial element to the development of artificial
biofeedback systems that are useful in blood glu-
cose control, drug dosing and administration, and
intravenous infusion of nutrients. In general, de-
vices in clinical use can be classified into three
categories based on their size and site for appli-
cations: bedside units, wearable modules, and im-
plantable devices. The bedside unit is a rather
large and complex device containing a miniatur-
ized sensor system used in the hospitals or inten-
sive care units. Wearable modules can be at-
tached to certain parts of the patient’s body and
are presently used in research for short-term
monitoring of certain clinical entities. Implant-
able devices offer the convenience of being used as
either a monitoring or an alarm device for con-
tinuous detection of certain substance levels in
vivo. However, issues such as biocompatibility,
generation of immune response to the sensor,
long-term fouling of the electrode, and the need
for frequent calibration still remain as major con-
cerns for the successful application of implantable
biosensors in vivo. The current trend in sensor
development leans towards miniaturization and
integration of the device.77–80 At the present time,
enzyme-immobilized sensors capable of monitor-
ing a variety of >10 different substances have al-
ready been commercialized, and a significant
amount of effort is underway to further broaden
the scope of applications.
IMMOBILIZED ENZYMES USED
IN BIOREACTORS
The therapeutic application of immobilized en-
zyme in a bioreactor started as early as the 1960s.
Since then, significant efforts have been made to
apply this technology to the correction of inborn
errors of metabolism, cancer treatment, blood de-
toxification, and removal of waste metabolites.
Generally speaking, the enzyme(s) can be either
immobilized on a solid support or encapsulated in
sol–gel or an artificial cell (red blood cell or lipo-
some) to construct the bioreactor. Although there
are some reports on the immobilization of en-
zymes including phospholipase A2 and hepari-
nase 81–83 in bioreactors for blood detoxification,
most efforts have been centered on the applica-
tion of encapsulated enzymes for disease treat-
ment. Compared with immobilized enzyme, en-
zymes entrapped in an artificial cell not only con-
vert substrates that diffuse into the cell, but also
possess low immunogenicity (due to the ability of
artificial cells to mask their immune determi-
nants) and prolonged blood clearance time. Ini-
tially, only a few enzymes, such as asparaginase
and urease, had been used. Also, encapsulation of
only single enzymes in the artificial cell had been
attempted. At present, however, multiple en-
zymes are being encapsulated in one artificial
cell, and such a multienzyme system has been
used for the correction of metabolic imbal-
ances.84–87 Recent examples of utilizing immobi-
lized enzymes for clinical applications include ar-
tificial cells containing enzymes such as SOD,88
asparaginase,89,90 urease,91 lactate oxidase,92 and
alcohol oxidase84,87 for replacing hereditary en-
zyme deficiency, suppressing the growth of
lymphosarcoma, decreasing systemic urea and
lactate concentrations, and treating alcohol poi-
soning, respectively. Most recently, there is a
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tendency of utilizing cells that can self-express
enzymes rather than encapsulating enzymes in
the artificial cells.93–95 Table 2 provides samples
of bioreactors that have been extensively investi-
gated during the last several years. Discussion of
the most recent development in this field is clas-
sified into three categories: red blood cells as a
carrier for enzymes, liposomes as a carrier for en-
zymes, and encapsulation of enzymes in sol–gel.
Red Blood Cell as A Carrier for Enzymes
As a new therapeutic approach, human and ani-
mal red blood cells (RBCs) have been used as the
carrier vehicle for a number of exogenous enzyme
drugs intended to be disseminated in an organ-
ism.103 Because of their biocompatible nature,
these cells will elicit little or virtually no immune
response, thereby providing advantages of pro-
tecting the activity of encapsulated substances
from rapid clearance and of avoiding toxic side
effects.104,105 In addition, RBCs can be readily ob-
tained, and a large quantity of the drug can be
entrapped into a rather small volume of the cell
using certain well-defined methods.
Techniques for induction of exogenous sub-
stances into RBCs include endocytosis,106 passive
diffusion,107 electroporation,84 and hypotonic di-
alysis/isotonic resealing,108 etc. Among them, hy-
potonic dialysis/isotonic resealing is currently the
most widely used technique because it is simple to
use, it provides an efficient encapsulation of a
large amount of the protein, it is adaptable for
scale-up purposes, and it provides a carrier cell
possessing the same in vivo half-life as that of the
normal RBC.109
Electroporation is another simple and efficient
method for enzyme encapsulation. If the intensity
of the electric field and the exposure time are
maintained below certain critical values, the
membrane rupture process required can be con-
trolled to be completely reversible. Compared
with hypotonic dialysis, electroporation provides
several advantages, such as the preparation of
the cell suspension can be achieved in an isotonic
solution and the procedure can be manipulated
easily and carried out routinely.84 In addition to
the loading techniques, the sources of RBCs can
also affect the capacity for drug loading. Among
different animal species from which the RBCs are
obtained and treated with the hypotonic dialysis
technique, the rat and rabbit have been reported
to be the species that could present problems for
enzyme encapsulation because these RBCs yield
relatively low drug-loading capacity compared
with human erythrocytes.103,110
Different methods employed in enzyme encap-
sulation could result in change in the properties
of erythrocytes. A previous investigation has re-
ported that erythrocytes to which the drug is
loaded by the osmotic method function as the best
drug carrier in systemic circulation because they
are more stable than erythrocytes to which the
drug is loaded by other methods.111 On the other
hand, chemically modified erythrocytes possess
the benefit of targeting the organs of the mono-
Table 2. Encapsulation of Enzymes in Artificial Cells
Enzyme (support) Function Potential Treatment Ref No.
Phosphotriesterase (liposome and
erythrocyte)
Degrading organophosphate Organophosphate poison 96, 97
Alcohol dehydrogenase, acetaldehyde
dehydrogenase (erythrocyte)





Bacterial infection 85, 86
Hydrogenase (erythrocyte) Catalyzing the oxidation of H2 Decompression sickness 98
Lactate oxidase (erythrocyte) Converting lactate to acetate Hyperlactatema 92
G-Asparaginase (liposome) Degrading G-asparagine Lymphoblastic leukemia 89–90
Superoxide dismutase (liposome) Cleaning superoxide Inflammation 99
DNA repair enzyme (liposome) Repairing DNA damage Skin aging and cancer 100, 101
Phospholipase A2 (liposome) Hydrolyzing of phospholipid Hypercholesterolemia 102
Cytochrome P450 (cells encapsulated
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nuclear phagocytic system because changes intro-
duced in the membrane of the erythrocyte by the
chemical method can be recognized by the macro-
phage cells. This recognition is shown by the fact
that although the liver is the main target, the
spleen provides the most selective removal of the
drug-loaded RBCs. In contrast, crosslinking of
Band 3, a prominent protein in the membrane
that is involved in a number of functions of the
erythrocyte, results in a more specific liver-
targeting erythrocyte carrier.111,112 Therefore,
manipulation of the erythrocyte membrane by
crosslinking can induce change in the distribution
of the erythrocyte carrier. So far, crosslinking of
erythrocytes with glutaraldehyde, dimethyl-
subrimidate, or toluene 2,4-diisocyanate have
been most widely attempted.
Liposome as a Carrier for Enzymes
Like RBCs, liposomes can also fulfill the promise
of a drug-carrier vehicle because of their ability to
reduce toxicity and enhance efficacy of the agents
that are encapsulated. However, therapeutic ap-
plication of liposomes administered by the intra-
venous route has been limited, primarily because
of a rapid clearance of liposomes from the blood-
stream and their uptake by the macrophage cells
in the liver and spleen.113 Recently, liposomes
with the ability to evade the rapid uptake by the
reticuloendothelial system (RES) have been de-
veloped, and a significant improvement in the
blood half-life has been achieved by using lipo-
somes whose surfaces are modified with polyeth-
yleneglycol (PEG).114,115 The stabilization of the
liposomes by PEG is due to the flexible dynamic
motion of the PEG polymer chains that sterically
prevent both electrostatic and hydrophobic inter-
actions between the blood components and the li-
posome surface.116 Because these liposomes ex-
hibit dramatically different pharmacokinetics
and biodistribution properties,114,115 they present
a new avenue with regard to therapeutic applica-
tions. Recent applications of the PEG-modified li-
posomes include use in enhancing efficacy of an-
tineoplastic agents against tumors, increasing de-
livery of antiinflammatory agents to the sites of
inflammation, and targeting the extravascular
system using such liposomes that are further
linked with the targeting ligands.117
Encapsulation of Enzymes in Sol–Gel
Sol–gel is a chemical synthesis technology em-
ployed in preparing gels, glasses, and ceramic
powders. Synthesis of materials by the sol–gel
process generally involves the use of metal alkox-
ides, mostly but not exclusively the SiO2 materi-
als, which undergo hydrolysis and condensation
polymerization reactions to produce the gel. It is
now a well-established knowledge for a wide va-
riety of enzymes and proteins that their reactivity
and function can be fully retained when they are
being confined within the pores of the sol–gel ma-
trix.118,119 The porosity of the sol–gel glass allows
small molecules to be diffused in, whereas the
large enzyme macromolecule remains physically
entrapped in the matrix. Sol–gel porous matrices
in general, and doped matrices in particular, pro-
vide the following advantages: (1) they possess
controllable surface area and relatively uniform
pore size and distribution; (2) they are thermally
stable; (3) they are able to enhance the stability of
the encapsulated enzymes; and (4) they can pre-
vent leaching of the entrapped enzyme. Recently,
new classes of precursors, based on polyol sili-
cates and polyol siloxanes and especially those
derived from glycerol, have been under intense
investigation.120 These precursors can be distin-
guished from the traditional ones by properties
such as being highly biocompatible and able to
encapsulate proteins and cells under mild condi-
tions in a reproducible manner.120 Such charac-
teristics enable the sol–gel carrier to address
most of the problems encountered with tradi-
tional encapsulation methods. To this regard, like
artificial cells, the sol–gel-entrapped enzymes
may also be used in a bioreactor for the treatment
of various enzyme-deficient diseases.118,119
CONCLUSION
This paper presents a brief review of recent (i.e.,
during the past decade) developments and medi-
cal applications of immobilized enzymes, particu-
larly in the areas of biosensors and bioreactors.
Although the progress in therapeutic use of im-
mobilized enzymes is slow and somewhat stag-
gered, because of the complexity of the human
body system to be applied, the future prospect for
application of immobilized enzymes in biosensing
is promising. This promising future is particu-
larly true because of the current advancement in
technologies in microprocessing and microelec-
tronic devices. Such technologies would allow the
biosensors to be miniaturized during manufactur-
ing, integrated with signal processing steps on a
chip, and arrayed for more complicated substrate
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analysis. In addition, the progress in optical
transducing devices provides another promising
avenue that can be incorporated in biosensor de-
velopment.
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